T2 relaxation time study of iron overload in b-thalassemia

  • S. I. Mavrogeni
  • E. D. Gotsis
  • V. Markussis
  • N. Tsekos
  • C. Politis
  • E. Vretou
  • D. Kremastinos


Myocardial iron deposition occurs as a result of blood transfusion therapy in b-thalassemia major patients. Since this deposition causes various cardiac complications, it is of interest to assess the iron content of the myocardium in relation to the clinical picture of the patients. Two different MRI indices were used to achieve this purpose: the T2 relaxation time and the heart/skeletal muscle signal intensity ratio. ECG gated spin echo images were obtained from 54 adult thalassemic patients, with a mean age of 26 (18–44) years, at TE = 22 ms and 60 ms, using a 1.5 T system. Patients were divided into 2 groups (A and B), according to their serum ferritin levels (> or < 2000 ng ml-1). Results were compared with nine controls, with a mean age of 25 (18–43) years. Heart T2 relaxation time in controls (44.3 ± 3.5 ms) was higher than in group A (29.9 ± 5.7 ms,P< 0.001) and group B (33.4 ± 6.8 ms,P < 0.01). T2 was measurable in 66% of group A and 83% of group B patients. The heart/muscle signal intensity ratio in group A (0.45 ± 0.27) was lower than in group B (0.82 ± 0.33,P < 0.001) and the controls (1.15 ± 0.20,P < 0.001). The heart/muscle signal intensity ratio was measurable in 94% of the patients and demonstrated an inverse relationship with the serum ferritin levels(r = - 0.52, P<0.01). This study indicates that the heart/muscle ratio is a sensitive index of iron overload and it can be measured in the majority of patients, irrespective of tissue iron concentration, thereby offering an advantage over the use of T2 relaxation time. © 1998 Elsevier Science B.V. All rights reserved.


b-Thalassemia Heart T2 relaxation time 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Kattamis C, Touliatos N, Haidas S, Matsaniotis N. Growth of children with thalassemia: effect of different transfusion regimens. Arch Dis Childhood 1970;45:502–6.Google Scholar
  2. [2]
    Propper RD, Cooper B, Rufo RR, et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977;297:418–23.PubMedCrossRefGoogle Scholar
  3. [3]
    Aldouri MA, Wonke B, Hoffbrand AV, et al. Iron state and hepatic disease in patients with thalassemia major treated with long-term subcutaneous desferrioxamine. J Clin Pathol 1987;40:1353–9.PubMedCrossRefGoogle Scholar
  4. [4]
    Engle MA. Cardiac involvement in Cooley’s anemia. Ann NY Acad Sci 1969;119:694–702.CrossRefGoogle Scholar
  5. [5]
    Kremastinos DT, Tsiapras D, Tsetsos G, Rentoukas E, Vretou H, Toutouzas P. Left ventricular diastolic Doppler characteristics in bthalassemia major. Circulation 1993;88:1127–35.PubMedGoogle Scholar
  6. [6]
    Jacobs A. The pathology of iron overload. In: Jacobs A, Worwood M, editors. Iron in biochemistry and medicine, II. New York: Academic Press, 1980:439–52.Google Scholar
  7. [7]
    Jacobs A, Miller F, Worwood M, Beamisch R, Wardrop C. Ferritin in the serum of normal subjects with iron deficiency and iron overload. Br Med J 1972;XX:206–211.Google Scholar
  8. [8]
    Crosby WH. Serum ferritin fails to indicate hemochromatosis: nothing gold can stay. N Engl J Med 1976;294:333–4.PubMedCrossRefGoogle Scholar
  9. [9]
    Green R, Watson LR, Saab GA, Crosby WH. ‘Normal’ serum ferritin: a caution. Blood 1977;50:545–7.PubMedGoogle Scholar
  10. [10]
    Ridson RA, Barry M, Flynn DN. Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassemia. J Pathol 1975;116:83–95.CrossRefGoogle Scholar
  11. [11]
    Liu P, Henkelman M, Joshi J, Waien S, Butany J, Olivieri N. Quantification of myocardial tissue iron contents using NMR relaxation. Validation in a novel murine thalassemia model. JACC 1992;19(3):187A (abstract 935-976).Google Scholar
  12. [12]
    Johnston DL, Rice L, Vick W, Hedrick TD, Rokey R. Assessment of tissue iron overload by nuclear magnetic resonance imaging. Am J Med 1989;87:40–7.PubMedCrossRefGoogle Scholar
  13. [13]
    Sechtem U, Higgins C. Relaxation measurements and contrast media. In: Underwood R, Finnin D, editors. Magnetic Resonance of the cardiovascular system. London: Blackwell, 1991:89–101.Google Scholar
  14. [14]
    Stark DD, Moseley ME, Bacon BR, et al. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Radiology 1985;154:137–42.PubMedGoogle Scholar
  15. [15]
    Gomori JM, Grossman RI, Drott HR. MR relaxation times and iron content of thalassemic spleens: an in vitro study. AJR 1988;150:567–9.PubMedGoogle Scholar
  16. [16]
    Vymazal J, Brooks RA, Zak O, McRill C, Shen C, Di Chiro G. T1 and T2 of ferritin at different field strengths: Effect on MRI. Magn Res Med 1992;27:368–74.CrossRefGoogle Scholar
  17. [17]
    Gomori JM, Horev G, Tamary H, et al. Hepatic iron overload: Quantitative MR imaging. Radiology 1991;179:367–9.PubMedGoogle Scholar
  18. [18]
    Worwood M, Cragg SJ, Jacobs A, McLaren C, Ricketts C, Economidou J. Binding of serum ferritin to concanavallin A: Patients with homozygous beta-thalassemia and transfusional iron overload. Br J Haematol 1980;46:409–16.PubMedGoogle Scholar
  19. [19]
    Olson LJ, Edwards WD, McCall JT, Ilstrup DM, Gersh BJ. Cardiac iron deposition in idiopathic hemochromatosis: histologic and analytic assessment of 14 hearts from autopsy. JACC 1987;10:1239–43.PubMedGoogle Scholar
  20. [20]
    Liu P, Olivieri N, Sullivan H, Henkelman M. Magnetic resonance imaging of cardiac iron overload in thalassemia: Detection of iron content and association with cardiac complications. JACC 1993;21(2):409A (abstract 948-119).Google Scholar
  21. [21]
    Zaino EC, Wielopolski L. In vivo measurement of hepatic and cardiac iron in Cooleys anemia by nuclear resonance scattering. Ann NYAcad Sci 1990;612:573–6.CrossRefGoogle Scholar
  22. [22]
    Dixon RM, Styles P, Al-Refaie F, et al. Assessment of hepatic iron overload in thalassemic patients by magnetic resonance spectroscopy. Hepatology 1994;19:904–10.PubMedCrossRefGoogle Scholar
  23. [23]
    Buja LM, Roberts WC. Iron in the heart: Etiology and clinical significance. Am J Med 1971;51:209–21.PubMedCrossRefGoogle Scholar
  24. [24]
    Houang MT, Skalicka A, Arozena X, Huehns ER, Shaw DG. Correlation between computed tomographic values and liver iron content in thalassemia major with iron overload. Lancet 1979;l:1322–33.CrossRefGoogle Scholar
  25. [25]
    Olivieri NF, Grisaru D, Daneman A, Martin DJ, Rose V, Freedman MH. Computed tomography scanning of the liver to determine eff∼cacy of iron chelation therapy in thalassemia major. J Pediatrics 1989;114:427–30.CrossRefGoogle Scholar
  26. [26]
    Brittenham G, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331:567–73.PubMedCrossRefGoogle Scholar
  27. [27]
    Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous b-thalassemia. N Engl J Med 1994;331:574–8.PubMedCrossRefGoogle Scholar

Copyright information

© Elsevier Science B.V. All rights reserved 1998

Authors and Affiliations

  • S. I. Mavrogeni
    • 1
  • E. D. Gotsis
    • 2
  • V. Markussis
    • 2
  • N. Tsekos
    • 3
  • C. Politis
    • 4
  • E. Vretou
    • 4
  • D. Kremastinos
    • 1
  1. 1.Onassis Cardiac Surgery CenterAthensGreece
  2. 2.Encephalos InstituteAthensGreece
  3. 3.University of MinnesotaMinneapolisUSA
  4. 4.Drakopoulion HospitalAthensGreece

Personalised recommendations